RT Journal Article SR Electronic T1 Clinical features and outcomes of patients with myasthenia gravis JF Neurosciences Journal JO Neurosciences (Riyadh) FD Prince Sultan Military Medical City SP 176 OP 184 DO 10.17712/nsj.2019.3.20190011 VO 24 IS 3 A1 Mohammed H. Alanazy YR 2019 UL http://nsj.org.sa/content/24/3/176.abstract AB Objectives: Objectives: To report clinical and laboratory features and outcomes of patients with autoimmune myasthenia gravis (MG) recruited from a single center in Saudi Arabia.Methods: We retrospectively reviewed prospectively collected data obtained from MG patients who have undergone examination and follow-up at our neuromuscular clinic between August 1, 2014 and January 31, 2019.Results: Ninety-five patients (55 females) were included. The mean age of onset of MG was 40.5±18.1 years in males and 31.3±15 years in females (p=0.009). The mean duration of follow-up at our clinic was 34.7±14.1 months, while the mean duration since MG onset was 8.0±7.2 years. Of all patients, 92.6% had generalized MG, 82.1% had acetylcholine receptor (AChR) antibodies, 4.2% had muscle-specific tyrosine kinase (MuSK) antibodies, 78.9% had early-onset MG with no second peak after age of 50 years, 22.1% had myasthenia crisis, 12.6% had refractory MG, 31.6% had thymic hyperplasia, 10.5% had thymoma, and 61.1% required ≥2 immunosuppressive therapies. At the last follow-up, 93 patients had achieved an optimal outcome (MG Foundation of America classification ≤ II). No patient with double-seronegative (dSN)-MG had thymoma, needed rituximab or intravenous immunoglobulin maintenance therapy, or was classified as refractory MG.Conclusion: Contrary to other studies, we did not observe a second-peak of MG onset. Clinical outcomes were favorable in the majority of our patients.